<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390685</url>
  </required_header>
  <id_info>
    <org_study_id>S-20180134</org_study_id>
    <secondary_id>2018-003416-50</secondary_id>
    <nct_id>NCT04390685</nct_id>
  </id_info>
  <brief_title>Prevention of Breast Cancer-related Lymphedma With Tacrolimus</brief_title>
  <acronym>BCRL-TACRO</acronym>
  <official_title>Prevention of Breast Cancer-related Lymphedma With Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer-related lymphedema is one of the most common and feared consequences of breast
      cancer treatment. Tacrolimus ointment may prevent lymphedema by inhibition of CD4+T cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphedema</measure>
    <time_frame>1 year</time_frame>
    <description>Arm size change &gt;= 10% using water displacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective changes assessed using the LYMPH-ICF (Lymphoedema Functioning, Disability and Health) questionaire</measure>
    <time_frame>1 year</time_frame>
    <description>Subjective change of lymphedema assessed by questionnaire. Range: 0-100. 100 being the most bothered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective changes assessed using DASH (DISABILITIES OF THE ARM, SHOULDER AND HAND) questionaire</measure>
    <time_frame>1 year</time_frame>
    <description>Subjective change of lymphedema assessed by questionnaire. Range: 1-5. 5 being the most bothered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective changes assessed using SF-36 questionnaire (Short form-36)</measure>
    <time_frame>1 year</time_frame>
    <description>Subjective change of lymphedema assessed by questionnaire. Range: 0-100. 0 being the most bothered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in L-DEX score using bioimpedance (Odense University Hospital Only).</measure>
    <time_frame>1 year</time_frame>
    <description>Change in L-DEX score of lymphedema arm derived from bioimpedance. Higher values mean more fluid in the lymphedema arm compared to the healthy arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lymph drainage. (Odense University Hospital Only).</measure>
    <time_frame>1 year</time_frame>
    <description>Change in lymph drainage assessed by indocyanine-green lymphangiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Tacrolimus ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apply whole arm, in a thin layer, once daily for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus ointment</intervention_name>
    <description>Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection</description>
    <arm_group_label>Tacrolimus ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Breast cancer with planned ALND

          -  postmenopausal or use of contraceptives

          -  good general health condition

          -  read and understand Danish

        Exclusion Criteria:

          -  Pregnant, breastfeeding it wishing to conceive with the next year

          -  bilateral breast cancer

          -  known allergy to tacrolimus or macrolides

          -  known lymphedema

          -  other malignant disease apart from keratinocyte cancer

          -  in medical treatment for diabetes mellitus

          -  known psychiatric condition which may influence participation

          -  known renal or hepatic function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mads G Jørgensen, MD</last_name>
    <phone>29210114</phone>
    <phone_ext>+45</phone_ext>
    <email>Mads.Gustaf.Jorgensen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens A Sørensen, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena F Carstensen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mette Tambour, PT</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Plastic and Reconstructive Surgery</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads G Jørgensen, MD</last_name>
      <email>Mads.Gustaf.Jorgensen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jens A Sørensen, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebælt Vejle</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Kjær, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kim G Ingwersen, PT</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mads Gustaf Jørgensen</investigator_full_name>
    <investigator_title>Medical doctor, ph.d.-student.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Starting 1 year after publication</ipd_time_frame>
    <ipd_access_criteria>Jens Ahm Sørensens review requests</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

